Connect public, paid and private patent data with Google Patents Public Datasets

Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules

Download PDF

Info

Publication number
US5049322A
US5049322A US07140246 US14024687A US5049322A US 5049322 A US5049322 A US 5049322A US 07140246 US07140246 US 07140246 US 14024687 A US14024687 A US 14024687A US 5049322 A US5049322 A US 5049322A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
nanocapsules
substance
phase
solvent
example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07140246
Inventor
Jean-Philippe Devissaguet
Hatem Fessi
Francis Puisieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE NATIONAL de la RECHERCHE SCIENTIFIQUE (CNRS) 15 QUAI DNATOLE FRANCE 75007 PARIS FRANCE
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/962Capsule, e.g. gelatin
    • Y10S514/963Microcapsule-sustained or differential release
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Abstract

The process according to the invention comprises:
(1) the preparation of a liquid phase consisting essentially of a solution of a substance A in a solvent or in a mixture of solvents, and containing the substance B in solution or as a dispersion,
(2) the preparation of a second liquid phase consisting essentially of a non-solvent or a mixture of non-solvents for the substances A and B, and supplemented with one or more surfactants, the solvent or mixture of solvents of the first phase being miscible in all proportions with the non-solvent or mixture of non-solvents of the second phase,
(3) the addition of the first phase to the second phase with moderate agitation so as to produce a colloidal suspension of nanocapsules, the wall of which is constituted by the substance A and the core by the substance B,
(4) if desired, the removal of all or part of the solvent or the mixture of solvents and of the non-solvent or the mixture of non-solvents so as to produce a colloidal suspension of nanocapsules of the desired concentration or to produce a powder of nanocapsules following the addition of stabilizing substances.

Description

The subject of the present invention is a novel procedure for the preparation of dispersible colloidal systems of a substance in the form of spherical particles of the vesicular type and of a size less than 500 nm (nanocapsules).

Nano-vesicular systems, including nanocapsules varying in size from 50 to 500 nm and consisting of a solid or liquid central core enveloped by a continuous, water-insoluble membrane, have already been described in the literature. The constituents of the membrane may be synthetic (polymers) or naturally-occurring (proteins) macromolecules, or lipids (liposomes).

Sub-microscopic polymeric particles possessing a diameter less than 500 nm are known, in particular from the patents Nos. BE-A-803 034, BE-A-839 748, BE-A-869 107, FR-A-2 504 408 and FR-A-2 515 960. According to BE-A-808 034 and -839 748, the sub-microscopic particles are formed by micellar polymerization of a monomer such as a derivative of acrylic acid. Similarly, BE-A-869 107, FR-A-2 504 408 and FR-A-2 515 960 describe the preparation of nanoparticles and of biodegradable nanocapsules obtained by the polymerization of an alkyl cyanoacrylate and containing a biologically active substance. The methods resort to polymerization in solution and are thus limited to using a limited number of polymers which can be prepared, in particular, by vinyl addition and are not suitable for naturally occurring or semi-synthetic polymers. Furthermore, it is difficult to control the molecular weight of the polymer constituting the nanoparticles and it is necessary, particularly when their biological use is under consideration, to remove the residual monomers and oligomers and, where necessary, the excess reagents involved in the polymerization reaction (initiator and catalyst), as well as surfactants if they are used at high concentration or are not biocompatible. In actual fact, the purification often proves to be onerous (ultracentrifugation, dialysis) since the filtration of the nanoparticles and nanocapsules is not always possible on account of their size.

The preparation of protein nanocapsules, in particular those made of gelatin. has also been described. Thus, Krause et al. (Pharm. Research, 239 (1985)) prepared nanocapsules of gelatin, the content of which was lipophilic (chloroform). starting from an emulsion of chloroform in a continuous aqueous phase (albumin solution). This emulsion is then desolvated by means of sodium sulfate. The nanocapsules are then hardened by means of glutaraldehyde, the excess of which must be destroyed by the use of sodium metabisulfite which, in turn, must be removed. Furthermore, the stability of the chloroform in the nanocapsule seems to be limited by its tendency to evaporate: the solvent may escape from the nanocapsules which, however, retain the lipophilic substance initially dissolved in the chloroform solution.

Unilamellar liposomes may be considered to be nanovesicles. The preparation is carried out by vigorous sonication of an aqueous disperson of phospholipids which leads to a particle size varying between 20 and 100 nm, but which entails the disadvantage of the risk of oxidation and other types of modification associated with sonication. Batzri et al. (Biochim. Biophys.Acta, 298, 1015 (1973)) suggested a method not involving sonication which is carried out by injecting (Hamilton syringe) a solution of egg white lecithin into a aqueous phase and which leads to the formation of unilamellar liposomes of about 25 nm. Nonetheless, this is a laboratory procedure which cannot be extended to other types of substances.

All of the methods described above are only applicable to certain classes of molecules and necessarily involve operations which are expensive (ultracentrifugation, sonication, etc) or hard to control (polymerization) without ensuring that the size of the particles is acceptably homogeneous or even that the particles are sufficiently small (less than 500 nm) such as would assure their long-term stability in the form of a colloidal suspension.

The invention proposes a new process for the preparation of nanocapulses which is free from the above-mentioned disadvantages and which can be used both for naturally occurring and synthetic polymeric substances and for various organic substances (medicines, lipids, etc) or minerals (salts, pigments. etc.) as well as for mixtures of them.

The subject of the invention is a process for the preparation of dispersible colloidal systems in the form of spherical particles of the vesicular type possessing a size less than 500 nm (nanocapsules), the wall of which is constituted by a substance A and the core by a substance B, comprising:

(1) the preparation of a liquid phase containing essentially of a solution of the substance A in a solvent or in a mixture of solvents containing substance B in solution or as a dispersion,

(2) the preparation of a second liquid phase consisting essentially of a non-solvent or a mixture of non-solvents for the substances A and B, and to which one or more surfactants are added, the solvent or the mixture of solvents of the first phase being miscible in all proportions with the non-solvents or mixture of non-solvents of the second phase,

(3) the addition of the first phase to the second phase with gentle agitation so as to produce a colloidal suspension of nanocapsules,

(4) if desired, the removal of all or part of the solvent or mixture of solvents or of the non-solvent or mixture of non-solvents so as to give rise to a colloidal suspension containing the desired concentration of nanocapsules or, following the addition of stabilizing substances, to lead to a powder of nanocapsules.

In step (3), the nanocapsules are formed practically instantaneously. The solution becomes milky white and shows the Tyndall effect characteristic of colloidal suspensions. At this stage, it is preferable to add the liquid phase prepared in step (1) to the liquid phase prepared in step (2), particularly if the latter is aqueous.

The "substance A" used according to the process of the invention may be practically any substance sufficiently soluble in a given solvent.

However, in view of the intended applications of the nanocapsules, the "substance A" is preferably a film-forming substance such as a polymer, either a synthetic polymer, for example poly (d,l) lactic acid (PLA) etc, a semi-synthetic polymer such, as for example, cellulose butyrate acetate, ethylcellulose, the phthalate of hydroxymethyl-propylcellulose (HPMCP), etc. or a naturally occurring polymer, for example gelatin, gum arabic, etc. Numerous other polymers can be used, for example: the aceto-phthalate of polyvinvyl, the aceto phthalate of cellulose; maleic acid derivatives (for example "Gantrez"); the copolymers of acrylic acid and acrylates and acrylic acid polymers (for example Eudragit®); d or l and (d,l) polylactic acid: the copolymers of lactic acid and glycolic acid, polypeptides, glycol derivatives (derivatives of propiolactone, butyrolactone, pivalolactone, ε-caprolactone, etc); the polymers obtained from cyclic esters of hydroxybutyric acid, hydroxyisobutyric sobutyric acid, hydroxymethylvaleric acid, phenyl-lactic acid, and hydroxyethylbutyric acid; poly beta benzyl malate: the copolymers of malic acid and benzyl malate; a polyvinylpyrrolidone-vinyl acetate cross-linked copolymer, the alkyl polycyanoacrylates; poly (ethylene-vinyl acetate); water-soluble polymers (gelatin, gum arabic, methylcellulose, etc); oligomers (styrene allyl alcohol), etc.

The "substance B" that it is desired to encapsulate in the substance A can be practically any substance soluble or dispersible in a given solvent.

The "substance B" may be a liquid such as a vegetable or a mineral oil, or any oily substance, for example olive oil, benzyl benzoate, isopropyl myristate, glycerides of fatty acids (for example a Miglyol®), volatile oils, etc.

The "substance B" may also be a biologically active substance, in particular an active medicinal ingredient or a precursor of an active medicinal ingredient or even a contrasting agent or a biological reagent.

The "substance B" may also be a pigment, an ink, a lubricant, an agent for treating surfaces, etc.

It is obvious that the process according to the invention can be applied equally to one substance B or several, for example an oil and a biologically active substance dissolved in this latter.

The "solvent" or the mixture of solvents used is a liquid capable of dissolving substance A and possibly substance B (for example, the polymer and possibly the biologically active substance). Moreover, the solvent must be miscible with the non-solvent for the substance used in the preparation. Thus, in most cases, the solvent will be an organic solvent such that the liquid phase (1) will constitute the organic phase whereas the liquid phase (2) will constitute the aqueous phase, but it is possible to use either two organic phases or two aqueous phases provided the conditions regarding solubility, insolubility and miscibility are met. On the other hand, the solvent must be sufficiently volatile for it to be removed if necessary. For example, in the case in which the substance is a polymer, the solvent may be chosen from among a lower alcohol (methanol, ethanol, isopropanol, etc), a lower ketone (acetone, methyl-ethyl-ketone, etc), a light hydrocarbon or a mixture of light hydrocarbons (hexane, petroleum ether, etc), a chlorinated light hydrocarbon (chloroform, methylene chloride, trichloroethylene, etc), or other common light solvents such as acetonitrile, dioxane. etc.

The "non-solvent" or the mixture of non-solvents for substances A and B is a liquid which does not dissolve these substances while being miscible with the solvent used. Thus, for example, when substance A is a polymer such as P.L.A., the solvent may be acetone and the non-solvent may be ethanol or distilled water; if the substance A is for example an acrylic polymer such as Eudragit L100®, the solvent may be an alkaline aqueous phase and the non-solvent may be an acidic aqueous phase.

The surfactant(s) (or emulsifying agents) added to the liquid phase (2) may be naturally occurring (lecithins), or synthetic, anionic (for example sodium laurylsulfate), cationic (for example quaternary ammonium) or non-ionic (for example, monoesters of sorbitan which may or may not contain a polyoxyethylene residue, ethers formed between fatty alcohols and polyoxyethylene glycols, polyoxyethylene-polypropylene glycol, etc). However, it is possible to add one or more surfactants of the same type as those mentioned above to the liquid phase (1) in order to improve the stability of the suspension in particular.

In step (4) the solvents and non-solvents may be completely removed, for example by lyophilization. In this way it is possible to obtain lyophilized nanocapsules which can be stored for long periods.

The proportion of surfactants in the colloidal suspension prepared in step (3) to which they have been added may vary in particular from 0.1% to 10% by weight, and lies preferably between 0.2 and 2% by weight.

In the case in which substance A is a polymer, the concentration of the polymer in the solvent or the mixture of solvents may vary between 0.1 and 10%, and lies preferably between 0.2 and 2% by weight.

The ratio of the volumes of solvents and non-solvents must be such as to allow the precipitation of the polymer. As this ratio increases, the size of the nanocapsules diminishes.

The moderate agitation of the preparation in step (3) is dependent on the amount of the substances utilized. It is not necessary for small quantities.

The effect of temperature and pH on the process according to the invention are limited so that it is usually not necessary to work under special conditions. However, when the two phases (1) and (2) used are aqueous, their respective pHs must be different in order for them to comply with the conditions of being a solvent and a non-solvent.

Moreover, the presence of an electrolyte (for example sodium chloride) does not appear to affect the production of nanocapsules. Thus, after the formation of the nanocapsules in step (3) a concentration of 25 mg/ml of sodium chloride does not lead to coalescence or precipitation of the nanocapsules formed.

The nanocapsules prepared according to the invention can be autoclaved if the physical properties of the substance permit this.

The process for the preparation of nanocapsules according to the invention offers the following advantages compared with known processes:

the production of nanocapsules smaller than 500 nm and in particular varying from about 150 to 450 nm by means of a simple method not requiring a supply of energy;

in the case in which the substance A forming the wall is a polymer, the nanocapsules are no longer obtained by polymerization of a monomer but by "nanoprecipitation" of a well-defined polymer;

the utilization of naturally occurring polymers as well as synthetic polymers which are known to be innocuous and which have been used for medical purposes for a very long time;

the utilization of polymers which are of the type which are biocompatible;

the possibility of using polymers which can dissolve in the organism once a particular pH value is attained, thus ensuring that polymer particles do not accumulate in the organism;

the possibility of using polymers which by their nature are bioresorbable, the products of heir degradation being completely innocuous;

the production of spherical capsules exhibiting only a slight variation in size and a content/container ratio which is very high (for example the ratio active ingredient/polymer).

The following examples illustrate the invention. The nanocapsules obtained are visible in the transmission electron microscope (x 25000-150000) and, after negative staining with phosphotungstic acid, appear as approximately round, non-contrasted particles.

EXAMPLE 1 Preparation of nanocapsules of a polymer containing an organic liquid

On the one hand, 125 mg of the copolymer of vinyl chloride and vinyl acetate (Rhodopas® AX 85-15) and 0.5 ml of benzyl benzoate are dissolved in 25 ml of acetone.

On the other hand, 125 mg of the mixed polymer formed between ethylene oxide and propylene glycol (Pluronic F68® or Poloxamer 188®), a non-ionic surfactant, are dissolved in 50 ml of purified water.

The acetone phase is poured into the aqueous phase with moderate magnetic stirring (about 100 r.p.m.). The aqueous phase immediately turns milky-white with bluish opalescence as a result of the formation of the nanocapsules, the wall of which is constituted by the vinyl copolymer and the core by benzyl benzoate.

The acetone is removed under reduced pressure (water pump vacuum) and the suspension is concentrated to the desired volume, for example 10 ml by removal of water under the same conditions.

The concentrated suspension is filtered through a glass frit (pores of 9-15 μm) and the diameter of the nanocapsules measured in a diffractometer equipped with a laser beam (Nanosizer® supplied by the Coultronics Company) is about 410 nm with a dispersion index of 2.

EXAMPLE 2 Preparation of nanocapsules of polymers containing indomethacin (lipophilic active ingredient)

(a) On the one hand, 125 mg of polyisobutylcyanoacrylate, 0.5 ml of benzyl benzoate and 15 mg of indomethacin are dissolved in 25 ml of acetone.

On the other hand, 125 mg of the mixed polymer formed between ethylene oxide and propylene glycol(Pluronic F68®) are dissolved in 50 ml of purified water.

The process then adopted is the same as that indicated in Example 1 and a suspension of nanocapsules is obtained, the diameter of which is about 240 nm with a dispersion index of 2. After ultracentrifugation, titration of indomethacin in the aqueous phase used as dispersion medium shows that the nanocapsules contain 98% of the active ingredient.

(b) Pharmacological assay:

When administered by the oral route to the fasted rat (5 mg/kg of indomethacin) the suspension of nanocapsules leads to a more rapid and more complete digestive absorption of the indomethacin than that observed after administration of the same dose of indomethacin in solution. After repeated administration to the fasted rat (5 mg/kg of indomethacin on 3 successive days) the suspension of nanocapsules results in improved digestive tolerance, as evidenced by the number of ulcerations and hemorrhages, compared with that observed after administration of the same dose of indomethacin in solution.

When administered by the intravenous route to the rat (5 mg/kg of indomethacin) the suspension of nanocapsules gives rise to a chronological profile of plasma concentrations of indomethacin which demonstrates an increased extravascular distribution of the active ingredient compared with that found after injection of indomethacin in solution (increase of the volume of distribution of indomethacin by a factor of approximately 2) followed by slower elimination (increase of the biological half-life of indomethacin by a factor of approximately 2).

EXAMPLE 3 Preparation of "empty" nanocapsules

The process described in Example 1 is employed but benzyl benzoate is replaced by ethyl ether (0.5 ml). After formation of the nanocapsules, the acetone and ether are carefully removed under reduced pressure (water pump) and the suspension of nanocapsules is concentrated to the desired volume, for example 10 ml, by removal of water.

The diameter of the nanocapsules is about 228 nm with a dispersion index of 1.5.

EXAMPLE 4 Preparation of nanocapsules of a polymer containing a lipophilic dye

The same process as that indicated in Example 3 is employed but 5 mg of Sudan III, a lipophilic dye, is added to the acetone phase.

After removal of the acetone and ether and concentration of the aqueous phase acting as dispersion medium to 10 ml, the diameter of the nanocapsules is about 175 nm with a dispersion index of 1.

The suspension of nanocapsules is then placed in contact with 5 ml of ethyl ether and the mixture is agitated by repeated inversion for a period of 5 mn. The ethereal phase remains colourless, thus demonstrating that the lipophilic dye has been completely encapsulated.

EXAMPLE 5 Preparation of nanocapsules of a polymer containing a hydrophilic dye

On the one hand, 125 mg of poly (d,l) lactic acid, 3.5 mg of ethythrosinc, a hydrophilic dye, and 0.4 ml of propylene glycol are dissolved in 25 ml of an acetone/tetrahydrofuran (50/50, v/v) mixture.

On the other hand, 0.8 ml of the mono-oleate of sorbitan (Span 80®), a non-ionic surfactant is dissolved in 50 ml of a heptane/silicone oil/acetone (80/10/10, v/v) mixture.

The acetone/tetrahydrofuran phase is added to the heptane/silicone/acetone phase with magnetic stirring. After concentration to a volume of 10 ml under reduced pressure, the diameter of the nanocapsules is about 490 nm with a dispersion index of 0.5.

The suspension of nanocapsules is agitated in the presence of 5 ml of purified water under the same conditions as those described in Example 4. The aqueous phase remains colourless, thus demonstrating that the hydrophilic dye has been completely encapsulated by the polymer.

EXAMPLE 6 Preparation of nanocapsules containing a lipid

The process employed is the same as that described in Example 1 but benzyl benzoate is replaced by a vegetable oil (peanut oil, for example). After filtration through a glass frit, trehalose (200 mg/ml) is added to the suspension to facilitate lyophilization, and the mixture is lyophilized. After resuspension of the powder of nanocapsules in 10 ml of purified water, their diameter is about 490 nm with a dispersion index of 2. Even after prolonged standing no phase separation is observed, thus demonstrating that the oil is still encapsulated in the polymer after lyophilization.

EXAMPLE 7 Preparation of nanocapsules of a polymer containing a mineral solid

On the one hand, 125 mg of an acrylic polymer (Eudragit L100, obtained from the Rohm-Pharma Company) are dissolved in 50 ml of purified water to which 2 ml of 0.1N sodium hydroxide solution is added.

On the other hand, 125 mg of a mixed polymer formed between ethylene oxide and propylene glycol (Pluronic F68®) are dissolved in 100 ml of purified water to which 0.45 ml of glacial acetic acid are added and 100 mg of particulate silicon carbide (mean diameter 450 nm, dispersion index 1) are dispersed in this phase.

The alkaline phase containing the polymer is added to the silicon carbide dispersed in the acidic phase with moderate magnetic stirring (about 100 r.p.m.). The acrylic polymer encapsulates the solid particles of silicon carbide and the nanocapsules thus obtained have a mean diameter of 475 nm with a dispersion index of 1.

It is possible that the nanocapsules produced according to the invention will find uses in many areas of technology, particularly those requiring microcapsules but considerably reduced in size (x 10-3), rendering their suspensions more stable and easier to use.

As "vectors" of medicines in human and animal therapy, the nanocapsules offer the prospects of:

attaining new sites of action, in particular intracellular sites, and even intralysosomal sites;

using new routes of administration for known medicines by increasing the stability and/or the absorption of the medicines, or by making available insoluble medicines in forms which can be injected by the intravascular route;

modifying the tissue distribution of the medicines by better targeting towards favourable sites of action and/or by diverting them from sites at which they produce undesirable, or even toxic, effects (improvement of the therapeutic index).

In pharmacy, the colloidal dispersions in the form of nanocapsules make it possible to:

prepare injectable forms of insoluble medicines,

stabilize a medicamentous active ingredient, and

prepare coatings of galenical forms starting from aqueous dispersions of film-forming polymers.

In the field of agrochemistry, the nanocapsule can be used as . vehicles for insecticides, pesticides etc. Their size leads to the expectation of a more powerful action as a result of better penetration through the cuticle. The low viscosity of the dispersion enables atomization to be carried out very easily in the form of droplets of very small size which are more efficacious because they provide more intimate covering.

In the area of paints, varnishes and treatment of surfaces in general, the nanocapsules may function as vehicles of pigments, reagents, strippers, etc. . . in the form of aqueous dispersions of very low viscosity, easy to atomize or apply and which can, if necessary, be made viscous and even adhesive (resuspension of the nanocapsules in an appropriate vehicle). The small size of the nanocapsules leads to a very fine deposition and to a very high homogeneity, for example, of pigmentation.

The nanocapsules prepared according to the invention can also be used in the fields of printing and reproduction graphics, the treatment of surfaces of textiles and fibres, photography, lubrication, etc. . .

Claims (13)

What we claim is:
1. A process for the preparation of dispersible colloidal systems in the form of spherical particles of the vesicular type and of a size less than 500 nm (nanocapsules), the wall of which is constituted by a substance A having film-forming properties and the core by a liquid substance B capable of being encapsulated by the substance A, comprising:
combining (1) a first liquid phase consisting essentially of a solution of the substances A and B in a solvent for the substances A and B or in a mixture of solvents for the substances A and B, and (2) a greater amount of a second liquid phase consisting essentially of a non-solvent or a mixture of non-solvents for the substances A and B and including one or more surfactants, the solvent or the mixture of solvents of the first phase being miscible in all proportions with the non-solvent or mixture of non-solvents of the second phase,
comprising a core of said liquid substance B surrounded by a layer of said substance A.
2. A process according to claim 1, wherein said combining step comprises adding the first liquid phase to the second liquid phase.
3. A process according to claim 1, wherein surfactant(s) are present in a proportion of 0.1 to 10% by weight of the colloidal suspension.
4. A process according to claim 3, wherein the surfactant(s) are present in a proportion of 0.2 to 2% by weight.
5. A process according to claim 1, wherein substance A is a polymer.
6. A process according to claim 5, wherein said polymer is present in said solvent in a concentration of between 0.1 and 10% by weight.
7. A process according to claim 6, wherein said polymer is present in a concentration of between 0.2 and 2% by weight.
8. A process according to claim 1, wherein substance B is a biologically active substance.
9. A process according to claim 1, wherein substance B is an oil.
10. A process according to claim 8, wherein substance B is a biologically active substance in solution in an oil.
11. A process according to claim 13, further comprising removing by lyophilization all of the solvents and non-solvents.
12. A process according to claim 1, wherein said nanocapsules are of a size of about 150 to 450 nm.
13. A process according to claim 1, further comprising removing at least a portion of the solvent or mixture of solvents and non-solvent or mixture of non-solvents to produce a concentrated colloidal suspension of nanocapsules or a powder of nanocapsules.
US07140246 1986-12-31 1987-12-31 Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules Expired - Lifetime US5049322A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR8618444A FR2608942B1 (en) 1986-12-31 1986-12-31 systems process for preparing colloidal dispersible of a substance in the form of nanocapsules
FR8618444 1986-12-31

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07666469 US5174930A (en) 1986-12-31 1991-03-06 Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US37158589 Continuation-In-Part 1989-06-26 1989-06-26

Publications (1)

Publication Number Publication Date
US5049322A true US5049322A (en) 1991-09-17

Family

ID=9342495

Family Applications (1)

Application Number Title Priority Date Filing Date
US07140246 Expired - Lifetime US5049322A (en) 1986-12-31 1987-12-31 Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules

Country Status (7)

Country Link
US (1) US5049322A (en)
JP (1) JPH0693998B2 (en)
CA (1) CA1293170C (en)
DE (1) DE3777793D1 (en)
EP (1) EP0274961B1 (en)
ES (1) ES2031529T3 (en)
FR (1) FR2608942B1 (en)

Cited By (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5308620A (en) * 1991-01-15 1994-05-03 Hemoshpere, Inc. Protein nanomatrixes and method of production
US5308624A (en) * 1990-04-03 1994-05-03 Laboratorios Cusi, S.A. Ophthalmic product
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5556617A (en) * 1991-09-13 1996-09-17 L'oreal Composition providing a lasting cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical application on the skin
WO1997003657A1 (en) * 1995-07-21 1997-02-06 Brown University Research Foundation A process for preparing microparticles through phase inversion phenomena
US5603986A (en) * 1994-03-09 1997-02-18 Nippon Paint Co., Ltd. Method of preparing microcapsules
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5705196A (en) * 1991-08-08 1998-01-06 Laboratorios Cusi, S.A. Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5851452A (en) * 1994-05-20 1998-12-22 Laboratorios Cusi, S.A. Process for coating droplets or nanometric particles
US5885491A (en) * 1993-04-20 1999-03-23 Laboratorios Cusi, S.A. Method to increase the stability of nanocapsules during storage thereof
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6071496A (en) * 1988-02-05 2000-06-06 Scharing Aktiengesellschaft Polyalkylcyanoacrylate agents and methods for enhancing contrast in ultrasound imaging
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6139818A (en) * 1990-05-18 2000-10-31 Bracco International B.V. Method of making ultrasonic contrast agent
US6190731B1 (en) * 1996-03-12 2001-02-20 Berhan Tecle Method for isolating ultrafine and fine particles and resulting particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2805761A1 (en) * 2000-03-02 2001-09-07 Mainelab Nanocapsules comprising (semi-) liquid lipid core and solid lipid shell, prepared by phase inversion methods, useful for administration of lipophilic or hydrophilic drugs by injection, orally or intranasally
WO2001080835A1 (en) * 2000-04-24 2001-11-01 Tanabe Seiyaku Co., Ltd. Process for producing microsphere
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
WO2002026892A1 (en) * 2000-09-26 2002-04-04 Basf Aktiengesellschaft Method for producing polymer coated pigment particles by precipitation
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US20020127278A1 (en) * 2000-12-22 2002-09-12 Kipp James E. Microprecipitation method for preparing submicron suspensions
US20030003155A1 (en) * 2000-12-22 2003-01-02 Kipp James E. Microprecipitation method for preparing submicron suspensions
US20030031719A1 (en) * 2000-12-22 2003-02-13 Kipp James E. Method for preparing submicron particle suspensions
US20030044433A1 (en) * 2000-12-22 2003-03-06 Jane Werling Method for preparing submicron suspensions with polymorph control
US20030059472A1 (en) * 2001-09-26 2003-03-27 Sean Brynjelsen Preparation of submicron sized nanoparticles via dispersion lyophilization
US20030059473A1 (en) * 2000-03-10 2003-03-27 Imed Montasser Method for preparing colloidal particles in the form of nanocapsules
US20030064027A1 (en) * 1990-05-18 2003-04-03 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20030100568A1 (en) * 2000-12-22 2003-05-29 Jane Werling Polymorphic form of itraconazole
US6585955B1 (en) 1990-04-02 2003-07-01 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US20030129137A1 (en) * 1992-11-02 2003-07-10 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US20030159615A1 (en) * 1998-11-20 2003-08-28 Freedom-2, Inc. Permanent, removable tissue markings
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20030175211A1 (en) * 1991-05-03 2003-09-18 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20030206959A9 (en) * 2000-12-22 2003-11-06 Kipp James E. Method for preparing submicron particle suspensions
US6677313B1 (en) 1995-07-21 2004-01-13 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20040057993A1 (en) * 2000-05-18 2004-03-25 Elan Pharma International Limited Rapidly disintegrating solid oral dosage form
US6720008B2 (en) 2002-01-22 2004-04-13 Pr Pharmaceuticals, Inc. Composition and method for the encapsulation of water-soluble molecules into nanoparticles
US20040076683A1 (en) * 2002-06-11 2004-04-22 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof, and use thereof as a carrier for active principle(s)
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US20040180004A1 (en) * 1992-11-02 2004-09-16 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US20040197269A1 (en) * 1990-04-02 2004-10-07 Bracco Research S.A. Ultrasound contrast media, contrast agents containing the media and method
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040245662A1 (en) * 2000-12-22 2004-12-09 Mahesh Chaubal Method for preparing submicron particles of antineoplastic agents
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US6844377B1 (en) * 1998-09-30 2005-01-18 Basf Aktiengesellschaft Polymer particles containing dye
US20050058605A1 (en) * 1990-04-02 2005-03-17 Michel Schneider Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US20050100595A1 (en) * 2001-08-08 2005-05-12 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US6896875B2 (en) 1990-04-02 2005-05-24 Bracco International B.V. Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging
US20050168426A1 (en) * 1999-05-21 2005-08-04 Seong-Hwan Moon Liquid crystal display
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
EP1683517A1 (en) 1996-08-19 2006-07-26 American Biosciences, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20060255323A1 (en) * 2003-11-28 2006-11-16 Mitsubishi Chemichal Corporation Process for producing fine particles of organic compound
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US20070009569A1 (en) * 1997-12-19 2007-01-11 Naomi Balaban Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
US20070059370A1 (en) * 2005-09-15 2007-03-15 Industrial Technology Research Institute Method and apparatus for fabricating nanoparticles
US20070071768A1 (en) * 2005-04-04 2007-03-29 Naomi Balaban Use of RIP in treating staphylococcus aureus infections
US20070092575A1 (en) * 2005-05-10 2007-04-26 Naomi Balaban Compositions for administering RNAIII-inhibiting peptides
US20070224279A1 (en) * 2001-09-14 2007-09-27 Elan Pharma International Ltd. Stabilization of chemical compounds using nanoparticulate formulations
US20080004356A1 (en) * 2006-02-04 2008-01-03 Bayer Materialscience Ag Process for preparing dispersible nanoparticles
US20080003295A1 (en) * 1999-10-08 2008-01-03 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20080124393A1 (en) * 1998-10-01 2008-05-29 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20080124350A1 (en) * 2002-09-24 2008-05-29 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
US20080160095A1 (en) * 1993-02-22 2008-07-03 Abraxis Bioscience, Llc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20080226732A1 (en) * 2002-03-20 2008-09-18 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080226572A1 (en) * 2006-12-20 2008-09-18 L'oreal Cosmetic emulsion containing silicone compounds
US20080226577A1 (en) * 2006-12-20 2008-09-18 L'oreal Cosmetic product comprising silicone compounds and an amphiphilic polymer
US20080254077A1 (en) * 2006-12-20 2008-10-16 L'oreal Core/shell particles based on silicone compounds
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US20080267876A1 (en) * 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
EP2011565A1 (en) 2007-07-05 2009-01-07 L'oreal Core/skin type capsules and preparation method
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20090119321A1 (en) * 2007-11-02 2009-05-07 International Business Machines Corporation Methods and computer program products for implementing low-cost pointer compression and decompression
US20090181100A1 (en) * 1998-11-12 2009-07-16 Elan Pharma International Ltd Dry powder aerosols of Nanoparticulate drugs
US20090203823A1 (en) * 2008-02-13 2009-08-13 Fujifilm Corporation Aqueous inkjet recording ink and method for producing the same
US20090221742A1 (en) * 2008-02-29 2009-09-03 Fujifilm Corporation Aqueous colorant dispersion, production method of aqueous colorant dispersion, and aqueous ink for inkjet recording
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
US7695739B2 (en) 2000-09-21 2010-04-13 Elan Pharma International Limited In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
US20100119827A1 (en) * 2006-04-25 2010-05-13 Research Foundation Of The City University Of New York Polymer submicron particle preparation by surfactant-mediated precipitation
US20100119464A1 (en) * 2008-07-10 2010-05-13 L'oreal Sun protection kit
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US20100285135A1 (en) * 2005-12-02 2010-11-11 Novartis Ag Nanoparticles For Use In Immunogenic Compositions
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US20110038900A1 (en) * 2008-04-28 2011-02-17 Novartis Ag Nanoparticles for use in pharmaceutical compositions
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US20110237748A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
WO2012006359A1 (en) 2010-07-06 2012-01-12 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
US8110616B2 (en) 2008-02-13 2012-02-07 Fujifilm Corporation Aqeous inkjet recording ink
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8263131B2 (en) 2000-12-22 2012-09-11 Baxter International Inc. Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8323641B2 (en) 2002-02-04 2012-12-04 Alkermes Pharma Ireland Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2012177986A2 (en) 2011-06-22 2012-12-27 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2583671A1 (en) * 2010-06-15 2013-04-24 Instituto de Pesquisas Tecnologicas do Estado de São Paulo S.A. IPT Colloidal nanoscale carriers for active hydrophilic substances and method for producing same
WO2013059898A1 (en) * 2011-10-24 2013-05-02 Universidade Federal De Ouro Preto - Ufop Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8658205B2 (en) 1998-01-14 2014-02-25 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
RU2539898C2 (en) * 2013-05-14 2015-01-27 Александр Александрович Кролевец Method for cephalosporin bioencapsulation
RU2540479C2 (en) * 2013-05-24 2015-02-10 Александр Александрович Кролевец Method for fenbendazole encapsulation
RU2543337C2 (en) * 2013-05-29 2015-02-27 Екатерина Евгеньевна Быковская Method of fenbendazole encapsulation
RU2543328C2 (en) * 2013-05-21 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Юго-Западный государственный университет" (ЮЗ ГУ) Method of obtaining particles of fragrances possessing supramolecular properties, encapsulated with fat-soluble polymer envelope
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
RU2544166C2 (en) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Method of producing zinc oxide microcapsules
RU2544169C2 (en) * 2013-04-09 2015-03-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Method for intestevit encapsulation
RU2543633C2 (en) * 2012-08-28 2015-03-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Method for fenbendazole encapsulation
RU2546516C2 (en) * 2013-07-08 2015-04-10 Александр Александрович Кролевец Method for producing penicillin microcapsules in kappa-carageenan
RU2545752C2 (en) * 2013-05-17 2015-04-10 Екатерина Евгеньевна Быковская Method of microcapsulation of cephalosporin antibiotics in poludanum
RU2554277C2 (en) * 2013-05-20 2015-06-27 Александр Александрович Кролевец Method of bioencapsulation of cephalosporin group medications
RU2554783C1 (en) * 2014-03-03 2015-06-27 Александр Александрович Кролевец Method of production of albendazole nanocapsules
RU2557950C2 (en) * 2013-12-17 2015-07-27 Александр Александрович Кролевец Method for producing microcapsules of antioxidants
RU2557939C2 (en) * 2013-07-05 2015-07-27 Александр Александрович Кролевец Method for producing microcapsules possessing supramolecular properties of "cherry" and "tomato" aromatic products
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP1343480B2 (en) 2000-12-21 2016-02-17 Alrise Biosystems GmbH Induced phase transition method for the production of microparticles containing hydrophobic active agents
RU2577692C1 (en) * 2014-09-09 2016-03-20 Александр Александрович Кролевец Method of producing nanocapsules of rosehip flavonoids
RU2577685C1 (en) * 2014-09-19 2016-03-20 Александр Александрович Кролевец Method of producing nanocapsules of potassium losartan in sodium alginate
RU2578403C2 (en) * 2014-05-12 2016-03-27 Александр Александрович Кролевец Method of producing nanocapsules of cytokinins
US9320707B2 (en) 1997-11-17 2016-04-26 Janssen Pharmaceutica, N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
RU2596476C1 (en) * 2015-04-27 2016-09-10 Александр Александрович Кролевец Method of producing nanocapsules of antispasmodic medicinal plants
RU2605848C2 (en) * 2014-10-10 2016-12-27 Александр Александрович Кролевец Method of producing nanocapsules of cephalosporin preparations in interferon
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054052T3 (en) * 1988-06-30 1994-08-01 Centre Nat Rech Scient Process for preparing dispersible colloidal systems of a protein in the form of nanoparticles.
GB2211408B (en) * 1987-10-28 1992-04-15 Nippon Shinyaku Co Ltd Parenteral drug carriers comprising fatty emulsions
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Physiologically active substance-containing polylactic acid microspheres and their preparation
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
FR2649888B1 (en) * 1989-07-18 1994-08-26 Exsymol Sa Products for cutaneous applications, has cosmetic effects and / or therapeutic
FR2659554B1 (en) * 1990-03-16 1994-09-30 Oreal Composition for the cosmetic treatment and / or pharmaceutical composition of the upper layers of the epidermis by topical application to the skin and preparation method thereof.
EP0486959B1 (en) * 1990-11-22 1996-08-28 Vectorpharma International S.P.A. Pharmaceutical composition of microparticles with controlled release and process of preparing it
FR2677223B1 (en) * 1991-06-05 1997-06-06 Jean Gueyne insecticide rotenone based composition, particularly for the treatment of human and animal parasites.
US5609878A (en) * 1991-06-05 1997-03-11 Gueyne; Jean Insecticide composition of rotenone microspheres
CA2078388A1 (en) * 1991-10-02 1993-04-03 Mridula Nair Biocompatible emulsion particles
FR2692167B1 (en) * 1992-06-16 1994-09-16 Centre Nat Rech Scient Preparation and application of new Nanovesicular dispersible colloidal systems based on cyclodextrin in the form of nanocapsules.
FR2692168B1 (en) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Preparation and use of new dispersible colloidal system based on cyclodextrin in the form of nanospheres.
ES2070778B1 (en) * 1993-10-07 1995-12-16 Vinas Lab Liposome composition and its obtention procedure.
WO1999033558A1 (en) * 1997-12-29 1999-07-08 Universite De Geneve Method for producing an aqueous colloidal dispersion of nanoparticles
US6013122A (en) * 1998-08-18 2000-01-11 Option Technologies, Inc. Tattoo inks
FR2787729B1 (en) * 1998-12-29 2001-01-26 Oreal Nanocapsules has basic water-dispersible anionic polymers, their method of preparing and cosmetic or dermatological compositions containing
FR2787730B1 (en) * 1998-12-29 2001-02-09 Oreal Nanocapsules based on poly (alkylene adipate), their process for the preparation and cosmetic or dermatological compositions containing
FR2790405B1 (en) * 1999-03-02 2001-04-20 Oreal Nanocapsules is based on dendritic polymers
EP1231905B1 (en) 1999-11-15 2009-04-08 BioCure, Inc. Responsive polymeric hollow particles
FR2864900B1 (en) 2004-01-09 2007-10-12 Oreal aqueous dispersion of nanocapsules with an oily core
JP4851067B2 (en) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 Nanoparticle-containing composition and method of manufacturing
FR2872703B1 (en) * 2004-07-07 2006-10-06 Ethypharm Sa Composite polymeric nanoparticles
FR2879476B1 (en) * 2004-12-21 2007-04-20 Univ Claude Bernard Lyon New process for the preparation of particles of which at least the peripheral surface is of polymeric nature, employing a membrane reactor
FR2910286B1 (en) 2006-12-20 2009-04-17 Oreal Composition comprising encapsulated silicone compounds
ES2384060B1 (en) * 2010-03-24 2013-09-23 Lipotec S.A. Capsules lipid nanoparticles.
FR2967573B1 (en) 2010-11-23 2012-11-09 Rhodia Poliamida E Especialida cosmetic kit and use to improve the appearance of the skin
RU2607654C2 (en) * 2014-10-10 2017-01-10 Александр Александрович Кролевец Method of producing nanocapsules of adenine in carrageenan
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE738604C (en) * 1935-07-09 1943-08-23 Rudolf Degkwitz Dr A process for producing hydrosols with selectable shape and selectable size of the colloidal particles
US3069370A (en) * 1958-12-22 1962-12-18 Upjohn Co Coacervation process for encapsulation of lipophilic materials
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
US3657144A (en) * 1967-06-05 1972-04-18 Ncr Co Encapsulation process
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
US3691090A (en) * 1969-01-16 1972-09-12 Fuji Photo Film Co Ltd Encapsulation method
US3748277A (en) * 1965-10-14 1973-07-24 Ncr Co Process of forming minute capsules
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016099A (en) * 1972-03-27 1977-04-05 Xerox Corporation Method of forming encapsulated toner particles
US4021364A (en) * 1972-12-04 1977-05-03 Prof. Dr. Peter Speiser Microcapsules in the nanometric range and a method for their production
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
US4118336A (en) * 1974-03-25 1978-10-03 Toyo Jozo Company, Ltd. Novel cellulose microcapsules and preparation thereof
US4124526A (en) * 1976-06-16 1978-11-07 Monsanto Company Encapsulation process and resulting aqueous dispersion of encapsulated droplets
US4460563A (en) * 1980-04-09 1984-07-17 Eurand S.P.A. Process for preparing microcapsules in a liquid vehicle
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
WO1986003676A1 (en) * 1984-12-21 1986-07-03 The Ohio State University Research Foundation Small particle formation and encapsulation
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE717134A (en) * 1968-08-05 1968-12-27
GB1497161A (en) * 1975-07-19 1978-01-05 Beecham Group Ltd Naphthyl derivatives

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE738604C (en) * 1935-07-09 1943-08-23 Rudolf Degkwitz Dr A process for producing hydrosols with selectable shape and selectable size of the colloidal particles
US3069370A (en) * 1958-12-22 1962-12-18 Upjohn Co Coacervation process for encapsulation of lipophilic materials
US3242051A (en) * 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
US3748277A (en) * 1965-10-14 1973-07-24 Ncr Co Process of forming minute capsules
US3657144A (en) * 1967-06-05 1972-04-18 Ncr Co Encapsulation process
US3691090A (en) * 1969-01-16 1972-09-12 Fuji Photo Film Co Ltd Encapsulation method
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
US4016099A (en) * 1972-03-27 1977-04-05 Xerox Corporation Method of forming encapsulated toner particles
US4021364A (en) * 1972-12-04 1977-05-03 Prof. Dr. Peter Speiser Microcapsules in the nanometric range and a method for their production
US4118336A (en) * 1974-03-25 1978-10-03 Toyo Jozo Company, Ltd. Novel cellulose microcapsules and preparation thereof
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
US4124526A (en) * 1976-06-16 1978-11-07 Monsanto Company Encapsulation process and resulting aqueous dispersion of encapsulated droplets
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4460563A (en) * 1980-04-09 1984-07-17 Eurand S.P.A. Process for preparing microcapsules in a liquid vehicle
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
WO1986003676A1 (en) * 1984-12-21 1986-07-03 The Ohio State University Research Foundation Small particle formation and encapsulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Nanoparticles and Nanocapsules--New Dosage Forms in the Nanometer Size Range", Pharm. Acta Helv., vol. 53, No. 2, 1978, by J. Kreuter, pp. 33-39.
Nanoparticles and Nanocapsules New Dosage Forms in the Nanometer Size Range , Pharm. Acta Helv., vol. 53, No. 2, 1978, by J. Kreuter, pp. 33 39. *

Cited By (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071496A (en) * 1988-02-05 2000-06-06 Scharing Aktiengesellschaft Polyalkylcyanoacrylate agents and methods for enhancing contrast in ultrasound imaging
US6177062B1 (en) 1988-02-05 2001-01-23 Schering Aktiengesellschaft Agents and methods for enhancing contrast in ultrasound imaging
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6881397B2 (en) 1990-04-02 2005-04-19 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6896875B2 (en) 1990-04-02 2005-05-24 Bracco International B.V. Mixable combination for generating a suspension of stable microbubbles for ultrasonic imaging
US20050058605A1 (en) * 1990-04-02 2005-03-17 Michel Schneider Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US20060034771A1 (en) * 1990-04-02 2006-02-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6585955B1 (en) 1990-04-02 2003-07-01 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040197269A1 (en) * 1990-04-02 2004-10-07 Bracco Research S.A. Ultrasound contrast media, contrast agents containing the media and method
US5308624A (en) * 1990-04-03 1994-05-03 Laboratorios Cusi, S.A. Ophthalmic product
US20040126322A1 (en) * 1990-05-18 2004-07-01 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6989141B2 (en) 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6139818A (en) * 1990-05-18 2000-10-31 Bracco International B.V. Method of making ultrasonic contrast agent
US20030064027A1 (en) * 1990-05-18 2003-04-03 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5308620A (en) * 1991-01-15 1994-05-03 Hemoshpere, Inc. Protein nanomatrixes and method of production
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5945033A (en) * 1991-01-15 1999-08-31 Hemosphere, Inc. Method for making non-crosslinked protein particles for therapeutic and diagnostic use
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5494683A (en) * 1991-01-25 1996-02-27 Eastman Kodak Company Surface modified anticancer nanoparticles
US20030175211A1 (en) * 1991-05-03 2003-09-18 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6592846B1 (en) 1991-05-03 2003-07-15 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure resistant gas-filled microvesicles and methods for thereof preparation thereof
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5705196A (en) * 1991-08-08 1998-01-06 Laboratorios Cusi, S.A. Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles
US5556617A (en) * 1991-09-13 1996-09-17 L'oreal Composition providing a lasting cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical application on the skin
US5993831A (en) * 1991-09-13 1999-11-30 L'oreal Composition providing a lasting cosmetic and/or pharmaceutical treatment of the upper epidermal layers by topical application on the skin
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US20030129137A1 (en) * 1992-11-02 2003-07-10 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US20040180004A1 (en) * 1992-11-02 2004-09-16 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US20080160095A1 (en) * 1993-02-22 2008-07-03 Abraxis Bioscience, Llc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6268053B1 (en) 1993-03-09 2001-07-31 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5885491A (en) * 1993-04-20 1999-03-23 Laboratorios Cusi, S.A. Method to increase the stability of nanocapsules during storage thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5603986A (en) * 1994-03-09 1997-02-18 Nippon Paint Co., Ltd. Method of preparing microcapsules
US5851452A (en) * 1994-05-20 1998-12-22 Laboratorios Cusi, S.A. Process for coating droplets or nanometric particles
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US6677313B1 (en) 1995-07-21 2004-01-13 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
WO1997003657A1 (en) * 1995-07-21 1997-02-06 Brown University Research Foundation A process for preparing microparticles through phase inversion phenomena
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6235224B1 (en) * 1995-07-21 2001-05-22 Brown University Research Foundation Process for preparing microparticles through phase inversion phenomena
US20100172998A1 (en) * 1995-07-21 2010-07-08 Edith Mathiowitz Process for preparing microparticles through phase inversion phenomena
US6616869B2 (en) 1995-07-21 2003-09-09 Brown University Research Foundation Process for preparing microparticles through phase inversion phenomena
US20040070093A1 (en) * 1995-07-21 2004-04-15 Brown University Research Foundation Process for preparing microparticles through phase inversion phenomena
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US6190731B1 (en) * 1996-03-12 2001-02-20 Berhan Tecle Method for isolating ultrafine and fine particles and resulting particles
US6372077B1 (en) 1996-03-12 2002-04-16 Berhan Tecle Method for isolating ultrafine and fine particles and resulting particles
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
EP1683517A1 (en) 1996-08-19 2006-07-26 American Biosciences, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
US9320707B2 (en) 1997-11-17 2016-04-26 Janssen Pharmaceutica, N.V. Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
US20070009569A1 (en) * 1997-12-19 2007-01-11 Naomi Balaban Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
US8067015B2 (en) * 1997-12-19 2011-11-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US9545457B2 (en) * 1998-01-14 2017-01-17 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US8747892B2 (en) 1998-01-14 2014-06-10 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US8685441B2 (en) 1998-01-14 2014-04-01 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US8658205B2 (en) 1998-01-14 2014-02-25 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US20150023880A1 (en) * 1998-01-14 2015-01-22 Lantheus Medical Imaging, Inc. Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6844377B1 (en) * 1998-09-30 2005-01-18 Basf Aktiengesellschaft Polymer particles containing dye
US20080124393A1 (en) * 1998-10-01 2008-05-29 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20090297619A1 (en) * 1998-10-01 2009-12-03 Elan Pharma International Ltd. Nanoparticulate anticonvulsant and immunosuppressive compositions
US20020012675A1 (en) * 1998-10-01 2002-01-31 Rajeev A. Jain Controlled-release nanoparticulate compositions
US6361798B1 (en) 1998-10-28 2002-03-26 Oakwood Laboratories, L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US20090181100A1 (en) * 1998-11-12 2009-07-16 Elan Pharma International Ltd Dry powder aerosols of Nanoparticulate drugs
US8124057B2 (en) 1998-11-12 2012-02-28 Alkermes Pharma Ireland Limited Propellant-based nanoparticulate dry powder aerosols and method of making
US7285364B2 (en) 1998-11-20 2007-10-23 The General Hospital Corporation Permanent, removable tissue markings
US6800122B2 (en) 1998-11-20 2004-10-05 Freedom-2, Llc Permanent, removable tissue markings
US7175950B2 (en) 1998-11-20 2007-02-13 The General Hospital Corporation Permanent, removable tissue markings
US20070107625A1 (en) * 1998-11-20 2007-05-17 Anderson Richard R Permanent, removable tissue markings
US6881249B2 (en) 1998-11-20 2005-04-19 The General Hospital Corporation Permanent, removable tissue markings
US7435524B2 (en) 1998-11-20 2008-10-14 The General Hosptial Corporation Permanent, removable tissue markings
US20050178287A1 (en) * 1998-11-20 2005-08-18 The General Hospital Corporation Permanent, removable tissue markings
US20030167964A1 (en) * 1998-11-20 2003-09-11 Freedom-2, Inc. Permanent, removable tissue markings
US20030159615A1 (en) * 1998-11-20 2003-08-28 Freedom-2, Inc. Permanent, removable tissue markings
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20050168426A1 (en) * 1999-05-21 2005-08-04 Seong-Hwan Moon Liquid crystal display
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US7850995B2 (en) * 1999-10-08 2010-12-14 Elan Pharma International, Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20080003295A1 (en) * 1999-10-08 2008-01-03 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US8057823B2 (en) 2000-03-02 2011-11-15 Universite D'angers Lipid nanocapsules, preparation process and use as medicine
WO2001064328A1 (en) * 2000-03-02 2001-09-07 Mainelab Lipid nanocapsules, preparation method and use as medicine
US20090238865A1 (en) * 2000-03-02 2009-09-24 Universite D'angers Lipid nanocapsules, preparation process and use as medicine
FR2805761A1 (en) * 2000-03-02 2001-09-07 Mainelab Nanocapsules comprising (semi-) liquid lipid core and solid lipid shell, prepared by phase inversion methods, useful for administration of lipophilic or hydrophilic drugs by injection, orally or intranasally
US20030152635A1 (en) * 2000-03-02 2003-08-14 Beatrice Heurtault Lipid nanocapsules, preparation process and use as medicine
US7348031B2 (en) * 2000-03-10 2008-03-25 Universite Claude Bernard Lyon I Method for preparing colloidal particles in the form of nanocapsules
US20030059473A1 (en) * 2000-03-10 2003-03-27 Imed Montasser Method for preparing colloidal particles in the form of nanocapsules
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US20060292183A1 (en) * 2000-03-22 2006-12-28 Mumper Russell J Microemulsions as precursors to solid nanoparticles
US20070154907A1 (en) * 2000-03-22 2007-07-05 Mumper Russell J Microemulsions as precursors to solid nanoparticles
WO2001080835A1 (en) * 2000-04-24 2001-11-01 Tanabe Seiyaku Co., Ltd. Process for producing microsphere
US20040057993A1 (en) * 2000-05-18 2004-03-25 Elan Pharma International Limited Rapidly disintegrating solid oral dosage form
US20080213371A1 (en) * 2000-05-18 2008-09-04 Elan Pharma International Limited Rapidly disintegrating solid oral dosage form
US20090130213A1 (en) * 2000-05-18 2009-05-21 Elan Pharma International Limited Rapidly disintegrating solid oral dosage form
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7695739B2 (en) 2000-09-21 2010-04-13 Elan Pharma International Limited In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
US8309136B2 (en) 2000-09-21 2012-11-13 Alkermes Pharma Ireland Limited In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
WO2002026892A1 (en) * 2000-09-26 2002-04-04 Basf Aktiengesellschaft Method for producing polymer coated pigment particles by precipitation
US6924035B2 (en) 2000-09-26 2005-08-02 Basf Aktiengesellschaft Method for producing polymer coated pigment particles by precipitation
US20030177943A1 (en) * 2000-09-26 2003-09-25 Helmut Auweter Method for producing polymer coated pigment particles by precipitation
EP1343480B2 (en) 2000-12-21 2016-02-17 Alrise Biosystems GmbH Induced phase transition method for the production of microparticles containing hydrophobic active agents
US20020127278A1 (en) * 2000-12-22 2002-09-12 Kipp James E. Microprecipitation method for preparing submicron suspensions
US20030031719A1 (en) * 2000-12-22 2003-02-13 Kipp James E. Method for preparing submicron particle suspensions
US8263131B2 (en) 2000-12-22 2012-09-11 Baxter International Inc. Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030003155A1 (en) * 2000-12-22 2003-01-02 Kipp James E. Microprecipitation method for preparing submicron suspensions
US20030044433A1 (en) * 2000-12-22 2003-03-06 Jane Werling Method for preparing submicron suspensions with polymorph control
US20030100568A1 (en) * 2000-12-22 2003-05-29 Jane Werling Polymorphic form of itraconazole
US20040245662A1 (en) * 2000-12-22 2004-12-09 Mahesh Chaubal Method for preparing submicron particles of antineoplastic agents
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030206959A9 (en) * 2000-12-22 2003-11-06 Kipp James E. Method for preparing submicron particle suspensions
US20020168402A1 (en) * 2000-12-22 2002-11-14 Kipp James E. Microprecipitation method for preparing submicron suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US8524829B2 (en) 2001-08-08 2013-09-03 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20050100595A1 (en) * 2001-08-08 2005-05-12 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20110166218A1 (en) * 2001-08-08 2011-07-07 Edith Mathiowitz Methods for micronization of hydrophobic drugs
US20070224279A1 (en) * 2001-09-14 2007-09-27 Elan Pharma International Ltd. Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US6835396B2 (en) 2001-09-26 2004-12-28 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
US8722091B2 (en) 2001-09-26 2014-05-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion lyophilization
US20030059472A1 (en) * 2001-09-26 2003-03-27 Sean Brynjelsen Preparation of submicron sized nanoparticles via dispersion lyophilization
US20050037083A1 (en) * 2001-09-26 2005-02-17 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US6720008B2 (en) 2002-01-22 2004-04-13 Pr Pharmaceuticals, Inc. Composition and method for the encapsulation of water-soluble molecules into nanoparticles
US8323641B2 (en) 2002-02-04 2012-12-04 Alkermes Pharma Ireland Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US8652464B2 (en) 2002-02-04 2014-02-18 Alkermes Pharma Ireland Limited Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20080279949A1 (en) * 2002-03-20 2008-11-13 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080226732A1 (en) * 2002-03-20 2008-09-18 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040076683A1 (en) * 2002-06-11 2004-04-22 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof, and use thereof as a carrier for active principle(s)
US20110165251A1 (en) * 2002-07-16 2011-07-07 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20080124350A1 (en) * 2002-09-24 2008-05-29 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
US20060255323A1 (en) * 2003-11-28 2006-11-16 Mitsubishi Chemichal Corporation Process for producing fine particles of organic compound
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
US8586005B2 (en) 2004-06-04 2013-11-19 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US7824691B2 (en) * 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
US20070071768A1 (en) * 2005-04-04 2007-03-29 Naomi Balaban Use of RIP in treating staphylococcus aureus infections
US20070092575A1 (en) * 2005-05-10 2007-04-26 Naomi Balaban Compositions for administering RNAIII-inhibiting peptides
US20070059370A1 (en) * 2005-09-15 2007-03-15 Industrial Technology Research Institute Method and apparatus for fabricating nanoparticles
US20080267876A1 (en) * 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
US20100285135A1 (en) * 2005-12-02 2010-11-11 Novartis Ag Nanoparticles For Use In Immunogenic Compositions
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
US7732498B2 (en) * 2006-02-04 2010-06-08 Bayer Materialscience Ag Process for preparing dispersible nanoparticles
US20080004356A1 (en) * 2006-02-04 2008-01-03 Bayer Materialscience Ag Process for preparing dispersible nanoparticles
US20100119827A1 (en) * 2006-04-25 2010-05-13 Research Foundation Of The City University Of New York Polymer submicron particle preparation by surfactant-mediated precipitation
US20080254077A1 (en) * 2006-12-20 2008-10-16 L'oreal Core/shell particles based on silicone compounds
US20080226577A1 (en) * 2006-12-20 2008-09-18 L'oreal Cosmetic product comprising silicone compounds and an amphiphilic polymer
US20080226572A1 (en) * 2006-12-20 2008-09-18 L'oreal Cosmetic emulsion containing silicone compounds
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US9555011B2 (en) 2007-04-13 2017-01-31 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
US9023395B2 (en) 2007-04-13 2015-05-05 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2011565A1 (en) 2007-07-05 2009-01-07 L'oreal Core/skin type capsules and preparation method
US20090119321A1 (en) * 2007-11-02 2009-05-07 International Business Machines Corporation Methods and computer program products for implementing low-cost pointer compression and decompression
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US20090203823A1 (en) * 2008-02-13 2009-08-13 Fujifilm Corporation Aqueous inkjet recording ink and method for producing the same
US8178597B2 (en) 2008-02-13 2012-05-15 Fujifilm Corporation Aqueous inkjet recording ink and method for producing the same
US8110616B2 (en) 2008-02-13 2012-02-07 Fujifilm Corporation Aqeous inkjet recording ink
US8586648B2 (en) 2008-02-29 2013-11-19 Fujifilm Corporation Aqueous colorant dispersion, production method of aqueous colorant dispersion, and aqueous ink for inkjet recording
US20090221742A1 (en) * 2008-02-29 2009-09-03 Fujifilm Corporation Aqueous colorant dispersion, production method of aqueous colorant dispersion, and aqueous ink for inkjet recording
WO2009121631A2 (en) 2008-03-31 2009-10-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US9393295B2 (en) 2008-04-28 2016-07-19 Novartis Ag Nanoparticles for use in pharmaceutical compositions
US20110038900A1 (en) * 2008-04-28 2011-02-17 Novartis Ag Nanoparticles for use in pharmaceutical compositions
US9192551B2 (en) 2008-07-10 2015-11-24 L'oreal Sun protection kit
US20100119464A1 (en) * 2008-07-10 2010-05-13 L'oreal Sun protection kit
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US8618240B2 (en) 2010-03-26 2013-12-31 Cerulean Pharma, Inc. Methods and systems for generating nanoparticles
US20110237748A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US8404799B2 (en) 2010-03-26 2013-03-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
EP2583671A1 (en) * 2010-06-15 2013-04-24 Instituto de Pesquisas Tecnologicas do Estado de São Paulo S.A. IPT Colloidal nanoscale carriers for active hydrophilic substances and method for producing same
EP2583671A4 (en) * 2010-06-15 2014-08-06 Inst Pesquisas Tech Colloidal nanoscale carriers for active hydrophilic substances and method for producing same
WO2012006359A1 (en) 2010-07-06 2012-01-12 Novartis Ag Delivery of self-replicating rna using biodegradable polymer particles
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
US8809492B2 (en) 2011-01-28 2014-08-19 Cerulean Pharma Inc. Method for fabricating nanoparticles
WO2012177986A2 (en) 2011-06-22 2012-12-27 Vyome Biosciences Conjugate-based antifungal and antibacterial prodrugs
WO2013059898A1 (en) * 2011-10-24 2013-05-02 Universidade Federal De Ouro Preto - Ufop Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours
RU2543633C2 (en) * 2012-08-28 2015-03-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Method for fenbendazole encapsulation
RU2544169C2 (en) * 2013-04-09 2015-03-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова Министерства сельского хозяйства Российской Федерации Method for intestevit encapsulation
RU2539898C2 (en) * 2013-05-14 2015-01-27 Александр Александрович Кролевец Method for cephalosporin bioencapsulation
RU2544166C2 (en) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Method of producing zinc oxide microcapsules
RU2545752C2 (en) * 2013-05-17 2015-04-10 Екатерина Евгеньевна Быковская Method of microcapsulation of cephalosporin antibiotics in poludanum
RU2554277C2 (en) * 2013-05-20 2015-06-27 Александр Александрович Кролевец Method of bioencapsulation of cephalosporin group medications
RU2543328C2 (en) * 2013-05-21 2015-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Юго-Западный государственный университет" (ЮЗ ГУ) Method of obtaining particles of fragrances possessing supramolecular properties, encapsulated with fat-soluble polymer envelope
RU2540479C2 (en) * 2013-05-24 2015-02-10 Александр Александрович Кролевец Method for fenbendazole encapsulation
RU2543337C2 (en) * 2013-05-29 2015-02-27 Екатерина Евгеньевна Быковская Method of fenbendazole encapsulation
RU2557939C2 (en) * 2013-07-05 2015-07-27 Александр Александрович Кролевец Method for producing microcapsules possessing supramolecular properties of "cherry" and "tomato" aromatic products
RU2546516C2 (en) * 2013-07-08 2015-04-10 Александр Александрович Кролевец Method for producing penicillin microcapsules in kappa-carageenan
RU2557950C2 (en) * 2013-12-17 2015-07-27 Александр Александрович Кролевец Method for producing microcapsules of antioxidants
RU2554783C1 (en) * 2014-03-03 2015-06-27 Александр Александрович Кролевец Method of production of albendazole nanocapsules
RU2578403C2 (en) * 2014-05-12 2016-03-27 Александр Александрович Кролевец Method of producing nanocapsules of cytokinins
RU2577692C1 (en) * 2014-09-09 2016-03-20 Александр Александрович Кролевец Method of producing nanocapsules of rosehip flavonoids
RU2577685C1 (en) * 2014-09-19 2016-03-20 Александр Александрович Кролевец Method of producing nanocapsules of potassium losartan in sodium alginate
RU2605848C2 (en) * 2014-10-10 2016-12-27 Александр Александрович Кролевец Method of producing nanocapsules of cephalosporin preparations in interferon
RU2596476C1 (en) * 2015-04-27 2016-09-10 Александр Александрович Кролевец Method of producing nanocapsules of antispasmodic medicinal plants

Also Published As

Publication number Publication date Type
DE3777793D1 (en) 1992-04-30 grant
FR2608942B1 (en) 1991-01-11 grant
CA1293170C (en) 1991-12-17 grant
JP1960935C (en) grant
FR2608942A1 (en) 1988-07-01 application
ES2031529T3 (en) 1992-12-16 grant
EP0274961B1 (en) 1992-03-25 grant
JPS63232840A (en) 1988-09-28 application
JPH0693998B2 (en) 1994-11-24 grant
EP0274961A1 (en) 1988-07-20 application

Similar Documents

Publication Publication Date Title
Patravale et al. Nanosuspensions: a promising drug delivery strategy
Nishioka et al. Lymphatic targeting with nanoparticulate system
Quintanar-Guerrero et al. Influence of stabilizing agents and preparative variables on the formation of poly (D, L-lactic acid) nanoparticles by an emulsification-diffusion technique
Kawashima et al. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods
Santos-Magalhaes et al. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules
US5043161A (en) Small, oily, free-flowing, silky-smooth, talc-like, dry microcapsules and aqueous formulations containing them
Li et al. A novel biodegradable system based on gelatin nanoparticles and poly (lactic‐co‐glycolic acid) microspheres for protein and peptide drug delivery
US5665379A (en) Lipid particle forming matrix, preparation and use thereof
US6531160B2 (en) Microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle and cosmetic or dermatological compositions containing them
Chan et al. PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery
Formulating drug delivery systems by spray drying
Fresta et al. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs
US4652257A (en) Magnetically-localizable, polymerized lipid vesicles and method of disrupting same
US5025004A (en) Water-dispersible polymeric compositions
US5961990A (en) Cosmetic particulate gel delivery system and method of preparing complex gel particles
US4960814A (en) Water-dispersible polymeric compositions
Hayward et al. Tailored assemblies of block copolymers in solution: it is all about the process
Allémann et al. In vitro extended-release properties of drug-loaded poly (DL-lactic acid) nanoparticles produced by a salting-out procedure
US20040220081A1 (en) Nanoparticulate bioactive agents
US5407609A (en) Microencapsulation process and products therefrom
US6932984B1 (en) Method of microencapsulation
Blanco et al. Protein encapsulation and release from poly (lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants
Szoka et al. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation
Moghassemi et al. Nano-niosomes as nanoscale drug delivery systems: an illustrated review
US6048550A (en) Hydrophilic microparticles and methods to prepare same

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:DEVISSAGUET, JEAN-PHILIPPE;FESSI, HATEM;PUISIEUX, FRANCIS;REEL/FRAME:004922/0221

Effective date: 19880722

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12